Agomab Spain S.L.U.

Agomab Spain S.L.U. demonstrates a concentrated focus on addressing fibrotic complications within the gastrointestinal tract, particularly in patients with established inflammatory bowel conditions. The sponsor's research portfolio centers on therapeutic interventions targeting intestinal fibrosis and stricture formation, conditions that represent significant clinical challenges in chronic gastrointestinal disease management.

• Crohn's Disease Strictures
• Intestinal Fibrosis Mechanisms
• Fibrostenotic Complications

The therapeutic development program emphasizes novel approaches to managing stricturing phenotypes in inflammatory bowel disease, exploring mechanisms that may prevent or reverse pathological tissue remodeling in the intestinal wall.